Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

SRI SERM selected for NCI development program

Dec. 17, 2002

No objective antitumor responses in AML patients treated with PTK-787/ZK-222584

Dec. 16, 2002

New data on bryostatin 1 combined with fludarabine in CLL

Dec. 16, 2002

Tempostatin enters phase II trial for recurring bladder cancer

Dec. 16, 2002

Efficacy of bortezomib in hematological malignancies

Dec. 16, 2002

Cell Genesys and VectorLogics collaborate on second-generation oncolytic virus therapies

Dec. 16, 2002

GenVec and Fuso collaborate to develop targeted cancer therapy candidate

Dec. 16, 2002

The antisense oligonucleotide oblimersen sodium a highlight of the ASH meeting

Dec. 16, 2002

Partaject-delivered busulfan granted orphan drug status

Dec. 16, 2002

Pharmacological profile of VX-944, an IMPDH inhibitor, characterized at ASH meeting

Dec. 13, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...